SG11201401733VA - Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes - Google Patents
Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypesInfo
- Publication number
- SG11201401733VA SG11201401733VA SG11201401733VA SG11201401733VA SG11201401733VA SG 11201401733V A SG11201401733V A SG 11201401733VA SG 11201401733V A SG11201401733V A SG 11201401733VA SG 11201401733V A SG11201401733V A SG 11201401733VA SG 11201401733V A SG11201401733V A SG 11201401733VA
- Authority
- SG
- Singapore
- Prior art keywords
- vaccines
- vaccine
- creating
- methods
- dengue virus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 2
- 241000725619 Dengue virus Species 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161550982P | 2011-10-25 | 2011-10-25 | |
| PCT/US2012/061893 WO2013063248A1 (en) | 2011-10-25 | 2012-10-25 | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401733VA true SG11201401733VA (en) | 2014-09-26 |
Family
ID=48168485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401733VA SG11201401733VA (en) | 2011-10-25 | 2012-10-25 | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
Country Status (10)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606635SA (en) | 2012-02-16 | 2016-10-28 | Vlp Therapeutics Llc | Virus like particle composition |
| US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| EP3177720B1 (en) | 2014-08-08 | 2021-09-22 | VLP Therapeutics, Inc. | Virus like particle comprising modified envelope protein e3 |
| EP3191589A4 (en) * | 2014-09-11 | 2018-05-09 | VLP Therapeutics, LLC | Flavivirus virus like particle |
| KR102611235B1 (ko) * | 2016-04-13 | 2023-12-08 | 다케다 백신즈 인코포레이티드 | 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법 |
| CN105732777B (zh) * | 2016-05-05 | 2019-06-04 | 中国人民解放军军事医学科学院微生物流行病研究所 | 黄热病毒特异性检测抗原及其应用 |
| EP3621645A4 (en) | 2017-05-10 | 2021-01-27 | University of Massachusetts | BIVALENT VACCINES AGAINST DENGUE / HEPATITIS B |
| TW201930335A (zh) | 2017-12-20 | 2019-08-01 | 美商Ｖｌｐ醫療股份有限公司 | α病毒複製子顆粒 |
| CN110343172B (zh) * | 2018-04-04 | 2021-09-03 | 中国科学院微生物研究所 | 一种高灵敏度的黄热病毒人源单克隆抗体及其应用 |
| CN109627294B (zh) * | 2018-12-29 | 2020-10-09 | 四川大学 | 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用 |
| EP4135847A4 (en) | 2020-04-17 | 2024-05-15 | VLP Therapeutics, Inc. | Coronavirus vaccine |
| MX2022013638A (es) | 2020-04-30 | 2023-01-24 | Vlp Therapeutics Inc | Inmunoterapia con citocina. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2372991B (en) * | 2001-03-09 | 2004-11-17 | Fiocruz Fundacao Oswaldo Cruz | Flavivirus expression vector |
| CN1551782A (zh) * | 2001-06-01 | 2004-12-01 | ��������ķ������ | 嵌合黄病毒载体 |
| ZA200802176B (en) * | 2005-08-10 | 2009-08-26 | Acambis Inc | Vaccination against dengue virus infection |
-
2012
- 2012-10-25 PH PH1/2014/500911A patent/PH12014500911A1/en unknown
- 2012-10-25 EP EP12842872.9A patent/EP2771366A4/en not_active Withdrawn
- 2012-10-25 BR BR112014009887A patent/BR112014009887A2/pt not_active IP Right Cessation
- 2012-10-25 US US13/660,653 patent/US20150265694A1/en not_active Abandoned
- 2012-10-25 HK HK15106951.7A patent/HK1206366A1/xx unknown
- 2012-10-25 CN CN201280052904.8A patent/CN104736568A/zh active Pending
- 2012-10-25 WO PCT/US2012/061893 patent/WO2013063248A1/en active Application Filing
- 2012-10-25 SG SG11201401733VA patent/SG11201401733VA/en unknown
- 2012-10-25 IN IN3925CHN2014 patent/IN2014CN03925A/en unknown
- 2012-10-25 HK HK14112282.6A patent/HK1198770A1/xx unknown
-
2014
- 2014-04-25 CR CR20140189F patent/CR20140189S/es unknown
-
2017
- 2017-01-23 US US15/413,347 patent/US10124053B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013063248A1 (en) | 2013-05-02 |
| US10124053B2 (en) | 2018-11-13 |
| PH12014500911A1 (en) | 2014-06-09 |
| EP2771366A4 (en) | 2015-06-03 |
| BR112014009887A2 (pt) | 2017-04-25 |
| CN104736568A (zh) | 2015-06-24 |
| IN2014CN03925A (enrdf_load_stackoverflow) | 2015-07-03 |
| CR20140189S (es) | 2014-09-24 |
| US20170202945A1 (en) | 2017-07-20 |
| US20150265694A1 (en) | 2015-09-24 |
| HK1198770A1 (en) | 2015-07-31 |
| EP2771366A1 (en) | 2014-09-03 |
| HK1206366A1 (en) | 2016-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201401733VA (en) | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes | |
| IL262123A (en) | Influenza virus vaccines and their uses | |
| IL261204A (en) | Influenza virus vaccines and their use | |
| ZA201404797B (en) | Influenza virus vaccines and uses thereof | |
| IL229307A0 (en) | Inactivated dengue virus vaccine | |
| EP2552479A4 (en) | INFLUENZA VIRUS VACCINES AND USES THEREOF | |
| PL2935313T3 (pl) | Szczepionki przeciwko wirusowi zapalenia wątroby typu b | |
| EP2595653A4 (en) | INFLUENZA VACCINE | |
| EP2806890A4 (en) | COMPOSITIONAL ANTIGEN SEQUENCES AND VACCINES | |
| IL231043A0 (en) | vaccine | |
| EP2876161A4 (en) | VACCINE | |
| PL2755680T3 (pl) | Preparaty szczepionkowe w postaci cząstek | |
| HUE059179T2 (hu) | Vízimadárban Mycoplasma-fertõzés megelõzésére szolgáló oltóanyag | |
| GB201119999D0 (en) | Vaccine | |
| EP2588135A4 (en) | Nanoemulsion vaccines | |
| SG11201502221WA (en) | Novel attenuated dengue virus strains for vaccine application | |
| EP2678043A4 (en) | RECOMBINANT MUMPSVIRUS VACCINE | |
| EP2763699A4 (en) | VACCINE | |
| EP2750703A4 (en) | VACCINES FOR HUMAN PAPILLOMAVIRUS AND METHODS OF USE | |
| EP2667891A4 (en) | COMBINATION VACCINES | |
| ZA201503036B (en) | Chimeric vaccine antigens against hepatitis c virus | |
| EP2929894A4 (en) | VACCINE ADJUVANS, PREPARATION AND VACCINES THEREOF | |
| EP2822599A4 (en) | VACCINE FORMULATION | |
| EP2701735A4 (en) | LIQUID VACCINE COMPOSITIONS | |
| ZA201404512B (en) | Malaria vaccine |